Relacorilant Clinical Trials (2026): 20 Studies for Healthy & Cushing Syndrome
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
20 Relacorilant clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 12 indications (including Healthy & Cushing Syndrome) and 1,863 total planned enrollment. 4 Phase 3 Relacorilant trials and 5 Phase 2 are listed. 3 Relacorilant clinical trials are actively recruiting at 32 U.S. sites across 21 states. Most recent activity: NCT05726292 (Apr 2028).
Where to Participate: All Relacorilant Trial Sites in the U.S. (32 sites across 21 states)
Every actively recruiting Relacorilanttrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Corcept Therapeutics Investigator Site #004 | Birmingham35233 | NCT06906341 | Map |
| AZ | Site 02 | Scottsdale85258 | NCT07259317 | Map |
| CA | Site 04 | Los Angeles90025 | NCT07259317 | Map |
| CA | Site 12 | Orange92868 | NCT07259317 | Map |
| CA | Corcept Therapeutics Investigator Site #150 | Palo Alto94304 | NCT06906341 | Map |
| CA | Corcept Therapeutics Investigator Site #014 | San Francisco94143 | NCT06906341 | Map |
| FL | Corcept Therapeutics Investigator Site #544 | Fort Myers33901 | NCT06906341 | Map |
| FL | Corcept Therapeutics Investigator Site #335 | Miami Beach33140 | NCT06906341 | Map |
| FL | Corcept Therapeutics Investigator Site #543 | West Palm Beach33041 | NCT06906341 | Map |
| GA | Site 06 | Atlanta30322 | NCT07259317 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60453 | NCT05726292 | Map |
| IN | Site 14 | Goshen46526 | NCT07259317 | Map |
| KS | Site 15 | Westwood66205 | NCT07259317 | Map |
| MI | Site 03 | Grand Rapids49503 | NCT07259317 | Map |
| MN | Corcept Therapeutics Investigator Site #518 | Minneapolis55404 | NCT06906341 | Map |
| MO | Corcept Therapeutics Investigator Site #334 | Kansas City64132 | NCT06906341 | Map |
| MO | Corcept Therapeutics Investigator Site #521 | St Louis63110 | NCT06906341 | Map |
| NJ | Site 10 | East Brunswick08816 | NCT07259317 | Map |
| NJ | Site 11 | Morristown07960 | NCT07259317 | Map |
| NM | Corcept Therapeutics Investigator Site #292 | Albuquerque97102 | NCT06906341 | Map |
| NY | Site 08 | Albany12206 | NCT07259317 | Map |
| NY | Site 07 | Shirley11967 | NCT07259317 | Map |
| OH | Corcept Therapeutics Investigator Site #304 | Centerville45459 | NCT06906341 | Map |
| OH | Site 13 | Cincinnati45219 | NCT07259317 | Map |
| OR | Corcept Therapeutics Investigator Site #517 | Eugene97401 | NCT06906341 | Map |
| PA | Corcept Therapeutics Investigator Site #127 | Pittsburgh15213 | NCT06906341 | Map |
| TN | Site 09 | Nashville37203 | NCT07259317 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT05726292 | Map |
| TX | Site 01 | San Antonio78229 | NCT07259317 | Map |
| VA | Corcept Therapeutics Investigator Site #522 | Fairfax22031 | NCT06906341 | Map |
| VA | Corcept Therapeutics Investigator Site #300 | Norfolk23502 | NCT06906341 | Map |
| WI | Corcept Therapeutics Investigator Site #121 | Milwaukee53226 | NCT06906341 | Map |
Relacorilant clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | Total |
|---|---|---|---|---|---|
| P1 | 10 | 10 | |||
| P1/P2 | 1 | 1 | |||
| P2 | 3 | 1 | 1 | 5 | |
| P3 | 1 | 2 | 1 | 4 |
Recruiting Relacorilant clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05726292 | A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | P2 | Prostate Cancer | 90 | Jan 2025 |
| NCT07259317 | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | P2 | Adenocarcinoma | 80 | Jan 2026 |
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | P2 | Ovarian Cancer | 270 | Apr 2025 |
Relacorilant clinical trials by indication
Healthy (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04795479 | — | P1 | completed | T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers |
| NCT06094738 | — | P1 | completed | A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects |
| NCT03512548 | — | P1 | completed | Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites |
| NCT03540836 | — | P1 | completed | A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants |
| NCT03457597 | — | P1 | completed | Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s |
| NCT03442621 | — | P1 | completed | Relacorilant Food Effect Study in Healthy Subjects |
Cushing Syndrome (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03604198 | — | P2 | active not recruiting | Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome |
| NCT03697109 | GRACE | P3 | completed | A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome |
| NCT05347979 | — | P1 | completed | Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants |
Prostate Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05726292 | — | P2 | recruiting | A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer |
| NCT03674814 | — | P1 | completed | Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer |
Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07259317 | — | P2 | recruiting | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma |
Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06906341 | — | P2 | recruiting | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers |
Ovarian Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05257408 | — | P3 | active not recruiting | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer |
Adrenocortical Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04373265 | — | P1 | completed | Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) |
Hypercortisolism (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04308590 | GRADIENT | P3 | completed | A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas |
Metastatic Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04329949 | RELIANT | P3 | terminated | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma |
Hepatic Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06094725 | — | P1 | completed | A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant |
Recurrent Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03776812 | — | P2 | completed | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02762981 | CORT125134 | P1/P2 | completed | Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors |
Relacorilant pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| GRADIENT | NCT04308590 | P3 | completed | Hypercortisolism | 137 | — |
| GRACE | NCT03697109 | P3 | completed | Cushing Syndrome | 152 | PMID 35058882 |
| RELIANT | NCT04329949 | P3 | terminated | Metastatic Pancreatic Ductal Adenocarcinoma | 43 | — |
Terminated and withdrawn Relacorilant trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04329949terminatedStudy of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
All Relacorilant trials (20)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05726292 | A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | P2 | recruiting | 90 | University of Chicago | Jan 2025 | |
| NCT07259317 | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | P2 | recruiting | 80 | Corcept Therapeutics | Jan 2026 | |
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | P2 | recruiting | 270 | Corcept Therapeutics | Apr 2025 | |
| NCT03604198 | Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | P2 | active not recruiting | 125 | Corcept Therapeutics | May 2018 | |
| NCT05257408 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | P3 | active not recruiting | 381 | Corcept Therapeutics | Jun 2022 | |
| NCT04308590 | GRADIENT | A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas | P3 | completed | 137 | Corcept Therapeutics | Jul 2020 |
| NCT03674814 | Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer | P1 | completed | 42 | University of Chicago | Oct 2018 | |
| NCT03697109 | GRACE | A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome | P3 | completed | 152 | Corcept Therapeutics | Nov 2018 |
| NCT04373265 | Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) | P1 | completed | 15 | Corcept Therapeutics | Sep 2020 | |
| NCT03776812 | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | P2 | completed | 178 | Corcept Therapeutics | Apr 2019 | |
| NCT05347979 | Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants | P1 | completed | 30 | Corcept Therapeutics | May 2022 | |
| NCT04329949 | RELIANT | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | P3 | terminated | 43 | Corcept Therapeutics | Jun 2020 |
| NCT04795479 | T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers | P1 | completed | 36 | Corcept Therapeutics | Jan 2021 | |
| NCT06094725 | A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant | P1 | completed | 30 | Corcept Therapeutics | Jan 2020 | |
| NCT06094738 | A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects | P1 | completed | 30 | Corcept Therapeutics | Sep 2020 | |
| NCT02762981 | CORT125134 | Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors | P1/P2 | completed | 85 | Corcept Therapeutics | May 2016 |
| NCT03512548 | Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites | P1 | completed | 52 | Corcept Therapeutics | Apr 2018 | |
| NCT03540836 | A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants | P1 | completed | 30 | Corcept Therapeutics | May 2018 | |
| NCT03457597 | Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s | P1 | completed | 27 | Corcept Therapeutics | Mar 2018 | |
| NCT03442621 | Relacorilant Food Effect Study in Healthy Subjects | P1 | completed | 30 | Corcept Therapeutics | Jan 2018 |
Relacorilant clinical trials: frequently asked questions
- How many Relacorilant clinical trials are there?
- 20 Relacorilant clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 14 are marked completed.
- Are Relacorilant clinical trials recruiting in 2026?
- Yes — 3 Relacorilant trials are actively recruiting in 2026, with 32 U.S. sites across 21 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Relacorilant being studied for?
- Relacorilant is being studied for Healthy, Cushing Syndrome, Peritoneal Neoplasms, Prostate Cancer, Fallopian Tube Cancer and 17 more. The trials are grouped by indication on this page.
- What phase is Relacorilant in?
- Relacorilant clinical trials span 4 Phase 3, 5 Phase 2, 10 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Relacorilant clinical trials?
- The lead sponsor across the most Relacorilant trials is Corcept Therapeutics, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Relacorilantas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: